M. Amir, Amir Gafoor, Z. Iqbal, Shehriyar Ashraf, Salma Zeb
{"title":"在资源匮乏的巴基斯坦2019冠状病毒病患者中同情地使用托珠单抗:一项试点研究","authors":"M. Amir, Amir Gafoor, Z. Iqbal, Shehriyar Ashraf, Salma Zeb","doi":"10.15212/bioi-2021-0019","DOIUrl":null,"url":null,"abstract":"\n Background: We herein report our experience of optimized utilization of tocilizumab for patients with coronavirus disease 2019 (COVID-19) in a limited-resource tertiary care hospital.Methods: This single-center, single-arm, open-label, interventional study was conducted to determine the effect of tocilizumab on the mortality of patients with COVID-19.Results: Fifty-nine patients were administered tocilizumab. Patients who received invasive respiratory support were identified to have a higher risk of mortality than those who received oxygen support.Conclusion: Our study showed that the maximum benefit of tocilizumab was observed as a prophylactic treatment of cytokine syndrome in patients with COVID-19, particularly those with moderate to severe symptoms who are not receiving invasive respiratory support.TOCIPAK https://ensaiosclinicos.gov.br/rg/RBR-25rtydq; REBEC Number 11773\n","PeriodicalId":431549,"journal":{"name":"BIO Integration","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Compassionate Use of Tocilizumab in Patients with Coronavirus Disease 2019 in a Low-resource Country, Pakistan: A Pilot Study\",\"authors\":\"M. Amir, Amir Gafoor, Z. Iqbal, Shehriyar Ashraf, Salma Zeb\",\"doi\":\"10.15212/bioi-2021-0019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n Background: We herein report our experience of optimized utilization of tocilizumab for patients with coronavirus disease 2019 (COVID-19) in a limited-resource tertiary care hospital.Methods: This single-center, single-arm, open-label, interventional study was conducted to determine the effect of tocilizumab on the mortality of patients with COVID-19.Results: Fifty-nine patients were administered tocilizumab. Patients who received invasive respiratory support were identified to have a higher risk of mortality than those who received oxygen support.Conclusion: Our study showed that the maximum benefit of tocilizumab was observed as a prophylactic treatment of cytokine syndrome in patients with COVID-19, particularly those with moderate to severe symptoms who are not receiving invasive respiratory support.TOCIPAK https://ensaiosclinicos.gov.br/rg/RBR-25rtydq; REBEC Number 11773\\n\",\"PeriodicalId\":431549,\"journal\":{\"name\":\"BIO Integration\",\"volume\":\"6 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BIO Integration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15212/bioi-2021-0019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BIO Integration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15212/bioi-2021-0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Compassionate Use of Tocilizumab in Patients with Coronavirus Disease 2019 in a Low-resource Country, Pakistan: A Pilot Study
Background: We herein report our experience of optimized utilization of tocilizumab for patients with coronavirus disease 2019 (COVID-19) in a limited-resource tertiary care hospital.Methods: This single-center, single-arm, open-label, interventional study was conducted to determine the effect of tocilizumab on the mortality of patients with COVID-19.Results: Fifty-nine patients were administered tocilizumab. Patients who received invasive respiratory support were identified to have a higher risk of mortality than those who received oxygen support.Conclusion: Our study showed that the maximum benefit of tocilizumab was observed as a prophylactic treatment of cytokine syndrome in patients with COVID-19, particularly those with moderate to severe symptoms who are not receiving invasive respiratory support.TOCIPAK https://ensaiosclinicos.gov.br/rg/RBR-25rtydq; REBEC Number 11773
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
